- Reaction score
- 392
News from Puretech Health
(Follica findings a Small molecule shown to amplify new hair growth during healing.
100 new hairs
•Short-term use, systemically safe options identified Near-term clinical development of a “game changing” platformFuture pipeline to further amplify effect)
" Enabling follicle neogenesis and skin rejuvenation through immune response to wounding
Founded by PureTech Health, Follica’s regenerative biology platform is based on seminal findings from the University of Pennsylvania that demonstrated the creation of skin organs (hair follicles) in adult mammals after abrasion.
This technology is being applied to treat androgenetic alopecia and other aesthetic-related indications.
Follica’s technology is the first, to PureTech’s knowledge, designed to create new follicles and hair through disruption of the skin, followed by treatment to enhance the effect.
Follica completed three human clinical studies of patients with androgenetic alopecia to demonstrate hair growth and new hair follicle formation and has been optimising its device and conducting tests in androgenetic alopecia and other aesthetic indications.
Follica has preclinical data which show the potential for next-generation proprietary compounds to further enhance the effect of new hair follicle formation.
Follica completed its clinical-stage development of a next-generation device and drug combination product for androgenetic alopecia, which is currently in an optimisation study.
Further phases of preclinical testing are also ongoing towards the prioritisation and development of next-generation, proprietary compounds based on Follica’s intellectual property.
Follica’s pivotal study is expected to commence following the completion of the optimisation study." (always the same words)
(Follica findings a Small molecule shown to amplify new hair growth during healing.
100 new hairs
•Short-term use, systemically safe options identified Near-term clinical development of a “game changing” platformFuture pipeline to further amplify effect)
" Enabling follicle neogenesis and skin rejuvenation through immune response to wounding
Founded by PureTech Health, Follica’s regenerative biology platform is based on seminal findings from the University of Pennsylvania that demonstrated the creation of skin organs (hair follicles) in adult mammals after abrasion.
This technology is being applied to treat androgenetic alopecia and other aesthetic-related indications.
Follica’s technology is the first, to PureTech’s knowledge, designed to create new follicles and hair through disruption of the skin, followed by treatment to enhance the effect.
Follica completed three human clinical studies of patients with androgenetic alopecia to demonstrate hair growth and new hair follicle formation and has been optimising its device and conducting tests in androgenetic alopecia and other aesthetic indications.
Follica has preclinical data which show the potential for next-generation proprietary compounds to further enhance the effect of new hair follicle formation.
Follica completed its clinical-stage development of a next-generation device and drug combination product for androgenetic alopecia, which is currently in an optimisation study.
Further phases of preclinical testing are also ongoing towards the prioritisation and development of next-generation, proprietary compounds based on Follica’s intellectual property.
Follica’s pivotal study is expected to commence following the completion of the optimisation study." (always the same words)
Last edited:
